Skip to main content
OpenTrials
Completed

NCT Number: NCT01295918

Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children

The purpose of this study is to determine if the daily intake of the probiotic Lactobacillus reuteri prevents antibiotic-associated diarrhoea and related Clostridium difficile infections in children and adolescents.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Antibiotic Associated Diarrhea Bacterial Infections Bacterial Infections and Mycoses Clostridium Difficile Infection Clostridium Infections Diarrhea Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Gram-Positive Bacterial Infections Infections Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

3 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Department of Pediatrics at St Marina University Hospital, Varna, Varna, Bulgaria

Loading trial locations.

About this study

Antibiotic-associated diarrhoea (AAD) occurs in up to 25% of all individuals receiving antibiotics (Bartlett, 2002). In hospitalized patients, AAD is related to significant increases in mortality, length of stay, and cost of medical care (McFarland, 2006). Twenty-nine percent of hospitalized patients may develop diarrhoea after antibiotic use; therefore, identifying strategies to minimize antibiotic-associated diarrhoea could be of significant medical and economic advantage (McFarland, 1998). A promising tool in this area is the probiotic Lactobacillus reuteri

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 3 - 18 years of age
  • Receiving antibiotics for not more than 48 hours prior to enrolment and free from diarrhoea
  • The signed informed consent by one/both parents / legal guardian and by the subject if she/he is 12 years or older
  • Available throughout the study period
  • No use of any other probiotic products during the study period (Bulgarian yoghurt without added probiotics can be used)
  • Subject or parents/guardian should have the mental ability to understand and willingness to fulfil all the details of the protocol

Exclusion criteria

  • Three or more soft and unformed or watery stools per day at admission
  • Receiving chemotherapy or radiation therapy
  • Diagnosis of inflammatory bowel disease
  • Enteral or parenteral nutrition only
  • Requiring care in an intensive care unit
  • Status post-bowel resection during hospitalization
  • Receiving antibiotics four weeks prior to hospitalization
  • Patient with severe life threatening illness or immunocompromised (HIV/AIDS, cancer, genetic disorders including cystic fibrosis, children with opportunistic infections, metabolic diseases)
  • Pregnancy
  • Lack of possibility to store the study product in a temperature below 25°C during the hot season of the year

Treatment and study plan

L reuteri in children on antibiotics

Dietary Supplement

Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.

Primary outcomes

  1. To assess if the probiotic L. reuteri is effective in preventing AAD in children

    Time frame: 2 years

    Incidence of diarrhea during and after treatment with antibiotics in patients ingesting L. reuteri versus placebo during the study period, measured as mean number of episodes per patient. An episode of diarrhea is defined as three or more (≥ 3) soft and unformed or watery bowel movements per day for at least 48 hours.

Secondary outcomes

  1. Incidence of mild diarrhea and severity if diarrhea in children with probiotic treatment

    Time frame: 2 years

    Incidence of mild diarrhoea during and after treatment with antibiotics in patients ingesting L. reuteri versus placebo during the study period is measured as mean number of episodes per patient. An episode of mild diarrhoea is defined as any soft and unformed or watery bowel movements not fulfilling the definition of AAD.

  2. Severity of diarrhoea in patients ingesting L. reuteri versus placebo

    Time frame: 2 years

    Severity of diarrhoea in patients ingesting L. reuteri versus placebo is measured as the total number of soft and unformed or watery bowel movements during an episode of diarrhoea and the presence of blood and mucus in faeces.

  3. Frequency of stool samples positive for C. difficile toxin A and B

    Time frame: 2 years

    Frequency of stool samples positive for C. difficile toxin A and B at baseline, when presenting with diarrhoea during the study period, and at the follow-up 21 days post-antibiotic treatment is done to detect possible clearance of C. difficile, in patients ingesting L. reuteri versus placebo.

  4. Frequencies of other gastrointestinal symptoms

    Time frame: 2 years

    Frequencies of other gastrointestinal symptoms during antibiotic use and 7 and 21 days after cessation of antibiotic use, in the L. reuteri group versus placebo is to be assessed by the validated GSRS score (Gastrointestinal Symptom Rating Score, Svedlund et al., 1988).

Sponsors and collaborators

Lead sponsor

St Marina University Hospital, Varna, Bulgaria

Other

Registry information

Official study title

Efficacy of the Probiotic Lactobacillus Reuteri in Prevention of Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children and Adolescents

Acronym: AADreuter

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Feb 15, 2011
Registry last updated
Sep 10, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.